Fundraising Fox

Qu Biologics

Burnaby · 1 known investors

qubiologics.com ↗

Qu Biologics develops Site Specific Immunomodulators (SSIs), a first-in-class immunotherapy platform intended to restore normal immune function. The company targets cancer, chronic inflammatory diseases, metabolic disease, and diseases of aging, and is running a Phase 2 clinical trial (PERIOP-06) of its QBECO SSI in late-stage colon cancer patients.

BiotechHealthtechin /qu-biologics-inc@qubiologics

Founders & leadership

SS
Simon SutcliffeExecutive Officer, Director
AR
Alun ReesExecutive Officer
RE
Robert E. PelzerDirector
ML
Michael LeschukDirector
HD
Harold David GunnExecutive Officer, Director
GV
Gillian VandermeirschExecutive Officer
JP
Jim PankovichExecutive Officer
JL
Julia LevyDirector

Investors · 1

Curitas VenturesStockholm

Reported raises · per SEC filings

Form D private placements
▶$48.8KraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Simon SutcliffeExecutive Officer, Director
  • Alun ReesExecutive Officer
  • Robert E. PelzerDirector
  • Michael LeschukDirector
  • Harold David GunnExecutive Officer, Director
  • Gillian VandermeirschExecutive Officer
  • Jim PankovichExecutive Officer
  • Julia LevyDirector
Offering amount
$77.6K
Amount sold
$48.8K
First sale
May 2018
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.